United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexitil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexitil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: magnesium stearate; carmellose calcium; maize starch; lactose monohydrate; macrogol 8000; hyprolose; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; maize starch; macrogol 8000; magnesium stearate; lactose monohydrate; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - candesartan cilexetil,hydrochlorothiazide -

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: carmellose calcium; magnesium stearate; lactose monohydrate; macrogol 8000; hyprolose; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; macrogol 8000; hyprolose; carmellose calcium; magnesium stearate; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - candesartan cilexetil,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - candesartan cilexetil,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: carmellose calcium; magnesium stearate; lactose monohydrate; macrogol 8000; hyprolose; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.